28 January 2026 | News
Image Courtesy: Public Domain
Multiply Labs today announced an agreement with AstraZeneca to evaluate the potential for applying GMP-ready robotic systems to commercial-scale cell therapy manufacturing. Multiply Labs is a current leader in autonomous manufacturing technology for advanced therapies.
The collaboration will focus on end-to-end robotic automation of industry-standard instruments used in cell therapy production using Multiply Labs’ robotic biomanufacturing system. The goal is to enable scalable, high-throughput manufacturing while maintaining the rigorous quality and regulatory standards required for clinical and commercial use.
“Cell therapies are among the most promising, yet complex medicines being developed today,” says Fred Parietti, PhD, CEO of Multiply Labs. “Our mission is to make these therapies more widely available by increasing manufacturing efficiency and scale. This agreement with AstraZeneca allows us to evaluate our multi-arm robotic clusters in a setting where we can combine some of the world’s best scientific and clinical expertise with our robotic platform to build the next generation of high-throughput, GMP-ready cell therapy manufacturing.”
Multiply Labs’ newest systems use four robotic arms operating in parallel to run a broad range of cell therapy manufacturing instruments already in use by the industry. This architecture minimizes the need for process modifications while maximizing output in existing facilities, targeting higher productivity.
